MSH2 and MLH1 have a central role in correcting mismatches in DNA occurring during DNA replication and have been implicated in the engagement of apoptosis induced by a number of cytotoxic anticancer agents. The function of MLH1 is not clearly defined, although it is required for mismatch repair (MMR) and engagement of apoptosis after certain types of DNA damage. In order to identify other partners of MLH1 that may be involved in signalling MMR or apoptosis, we used human MLH1 in yeast two-hybrid screens of normal human breast and ovarian cDNA libraries. As well as known partners of MLH1 such as PMS1, MLH3 and MBD4, we identified the carboxy terminus of the human c-MYC protooncogene as an interacting sequence. We demonstrate, both in vitro by yeast two-hybrid and GST-fusion pulldown experiments, as well as in vivo by coimmunoprecipitation from human tumour cell extracts, that MLH1 interacts with the c-MYC protein. We further demonstrate that the heterodimeric partner of c-MYC, MAX, interacts with a different MMR protein, MSH2, both in vitro and in vivo. Using an inducible c-MYC-ERt fusion gene, we show that elevated c-MYC expression leads to an increased HGPRT mutation rate of Rat1 cells and an increase in the number of frameshift mutants at the HGPRT locus. The effect on HGPRT mutation rate is small (2-3-fold), but is consistent with deregulated c-MYC expression partially inhibiting MMR activity.
Introduction
Inactivation of the mismatch repair genes hMLH1 and hMSH2 is the most frequent basis for loss of mismatch repair found in hereditary nonpolyposis colorectal cancer and sporadic tumours (Kuismanen et al., 2000) . In mammalian cells, the mismatch repair protein MSH2 forms heterodimers with MSH3 or MSH6 (Modrich and Lahue, 1996; Jiricny, 1998) . These heterodimers bind to mismatches and insertions (loops, insertion/deletions) in DNA, as well as certain types of DNA adducts, such as those induced by the anticancer drug cisplatin or monofunctional alkylating agents (Duckett et al., 1996; Yamada et al., 1997) . Binding of these heterodimers to mismatches leads to strandspecific mismatch repair, while recognition of DNA adducts can lead to cell death (Karran and Hampson, 1996; Modrich, 1997; Duckett et al., 1999; Toft et al., 1999) . MLH1 expression is also necessary for both these processes. MLH1 forms heterodimers with other MutL homologues, PMS2, PMS1 and MLH3, through a conserved putative coiled coil domain in the MutL partners (Kondo et al., 2001) . MLH1 can also interact with MBD4 (MED1), a methyl-CpG-binding domain protein (Bellacosa et al., 1999) . Interactions between MLH1 and the replication factor PCNA (proliferating cell nuclear antigen) have also been demonstrated, leading to the suggestion that MutL heterodimers act to interface MutS heterodimers bound to DNA mismatches and DNA replication components (Umar et al., 1996; Bowers et al., 2001) .
In order to identify other partners of MLH1 that may be involved in signalling MMR or apoptosis, we used MLH1 in yeast two-hybrid screens of a normal human breast and normal ovarian cDNA libraries. We report the identification of the carboxy terminus of the human c-MYC proto-oncogene as an interacting sequence. Expression of the c-MYC gene is closely related to cellular proliferation (Obaya et al., 1999) . In quiescent cells c-MYC expression is absent, although upon mitogen stimulation c-MYC expression is rapidly induced. c-MYC is a protein with diverse roles; a putative transcription factor that plays a role in the regulation of the cell cycle, differentiation and apoptosis (Henriksson and Luescher, 1996) . Binding to MAX is required for both the oncogenic and transactivation functions of c-MYC (Blackwood et al., 1991) . The function of MAX is to control the access of c-MYC protein to their physiological DNA recognition sequence, the E-box. MAX also interacts with the MAD family of proteins implicated in transcriptional repression, cell growth inhibition and differentiation (Schreiber-Agus and DePinho, 1998) . These interactions can compete with c-MYC: MAX heterodimers and inhibit transactivation and oncogenic potential of c-MYC. Therefore, we have examined the potential of MAX to bind to MMR proteins and show that, although unable to bind to MLH1, MAX can bind to MSH2.
Rat fibroblast cells have been previously shown to undergo cell cycle deregulation when c-MYC activity is induced using chimeras of c-MYC and steroid receptors (Eilers et al., 1989) . C-MYC fused to a tamoxifen inducible mutant murine oestrogen receptor (MYCERt) has been particularly exploited as a means of switching on c-MYC in these cells by treatment with 4-hydroxy tamoxifen (4OHT) (Littlewood et al., 1995) . We have used this 4OHT-inducible model to examine the potential effects of MYC-ERt expression on genetic stability of rat fibroblasts. Specifically, this conditional model of c-MYC expression was used to examine the mutation rate at the endogenous HGPRT gene (Bhattacharyya et al., 1994) .
Results

Yeast two-hybrid analysis of interactions between MLH1 and c-MYC
We have used human MLH1 as bait in yeast two-hybrid screens of human cDNA libraries from normal breast and ovarian tissues to identify genes encoding proteins capable of interacting with MLH1. These screens identified genes encoding proteins known to interact with MLH1, such as PMS1, MLH3 and MED1/MBD4 (Bellacosa et al., 1999; Raschle et al., 1999; Kondo et al., 2001) . A yeast two-hybrid screen of normal human Mammary Gland Matchmaker cDNA library (Clontech) identified the carboxy terminus of the human c-MYC proto-oncogene as an interacting sequence. The carboxy terminus of human and avian c-MYC, which contains the MAX binding basic region/helix-loophelix/leucine zipper (b/HLH/LZ) domain (Blackwood et al., 1991) , can interact with full-length MLH1 and a C-terminal (amino acids 515-756) fragment of MLH1 as assayed using yeast two-hybrid assays (Table 1) . Neither the c-MYC nor MLH1 constructs showed any evidence of self-activation when assayed by cotransformation with vector alone or vector expressing an irrelevant protein such as lamin. C-MYC also fails to interact with N-terminal regions of MLH1 (amino acids 1-579; data not shown). The region of MLH1 that interacts with c-MYC overlaps with the region of MLH1 required for heterodimerization with other MutL homologues (amino acids 492-742 (Kondo et al., 2001) ).
In order to address whether the leucine zipper motif of c-MYC was necessary for the interaction with MLH1, avian c-MYC mutants with C-terminal truncations of the leucine zipper motif of 10 and 27 amino acids, which have previously been shown to abolish MAX-binding and MYC-transforming activity (Crouch et al., 1993) , were analysed. These fail to bind MLH1 (Table 1) . However, a substitution of proline for lysine in helix 2 of the HLH motif of c-MYC (MycP-H2, lysine to proline at 377), that has also been shown to cause loss of MAX-binding and MYC-transforming activity (Crouch et al., 1993) , retains the capacity to bind to MLH1. Mutation of helix 1 (MycP-H1, phenylalanine to proline at 353) does not cause loss of MLH1 binding, similar to the lack of effect on MAX binding of this mutant (Crouch et al., 1993) . Thus, the binding of MLH1 to c-MYC is similar to MAX in requiring an intact leucine zipper domain, but appears to be distinct from MAX binding in that mutation of helix 2 does not disrupt MLH1 binding. A summary of the constructs used to examine interactions assayed by yeast twohybrid assays of MLH1 and c-MYC is shown in Figure 1 .
MLH1 and MSH2 interactions with MYC:MAX
In order to further establish an interaction of hMLH1 with c-MYC using an independent assay system, we examined the ability of hMLH1-GST fusion proteins to Hann et al., 1988) and bound proteins visualized. As shown in Figure 2a , hMLH1-GST and MAX-GST both bound c-MYC, while GST alone did not. Furthermore, when hMLH1-GST was mixed with cell extracts from a human promyelocytic cell line, K562, and interacting proteins visualized after GST-pull-down by Western analysis using anti c-MYC antibodies, c-MYC was observed to bind to full-length MLH1-GST fusion and a C-terminal (amino acids 515-756) GST fusion of MLH1, but not with more N-terminal fragments or GST alone ( Figure 2b ). As observed in the yeast two-hybrid analysis and as previously observed (Guerrette et al., 1999) , MLH1-GST forms a complex with PMS2 ( Figure 2b ). Similar results were observed using extracts from human A2780 cells and chick embryo fibroblasts (CEF) transformed with the v-myc-encoding tumour virus MC29 (data not shown). Thus, these GST-pulldown experiments using purified bacterially expressed hMLH1-GST fusion proteins confirm the observations from the yeast two-hybrid experiments that c-MYC interacts with full-length MLH1 and a carboxy terminus fragment of MLH1 (amino acids 515-756).
As well as confirming the interaction of c-MYC with MLH1, the GST-pull-down experiments identified an interaction between MAX, the heterodimeric partner of MYC, and MSH2 (Figure 2b ). There is no evidence of MAX interacting with MLH1 or GST alone under these conditions. An interaction between GST-MAX and MSH2 is observed in extracts from cisplatin-resistant A2780/cp70, cells that are deficient in MLH1 and PMS2 , as well as the cisplatinsensitive parental MLH1/PMS2 proficient A2780 line (Figure 2c,d ). Since MAX and MSH2 are coprecipitated from the MLH1/PMS2-deficient A2780/cp70 line, this argues that neither MLH1 nor PMS2 are required for the MAX: MSH2 interaction detected. Coimmunoprecipitation of MSH2 and MLH1 has been observed from human cell extracts under certain experimental conditions (Gu et al., 1998; Matton et al., 2000) . However, as shown in Fig. 2b , we were not able to detect any interaction between MLH1 and MSH2 using GST-pulldown analysis of cell extracts.
In vivo interactions of MMR proteins with MYC and MAX in human tumour cells
The observation that MAX is interacting with MSH2 raises the possibility that the MAX: MYC and MYC: MLH1 interaction may allow signalling from mis- Figure 3a ) and K562 promyelocytic cell extract (data not shown). Treatment of the cells with cisplatin, a DNA-damaging anticancer agent known to mediate toxicity in a mismatch-repair-dependent manner (Moreland et al., 1999) , did not increase the amounts of MLH1 or MYC immunoprecipitated. Immunoprecipitation of c-MYC by MLH1 antibodies was also detected, but only for the MC29 avian cell line, which expresses high levels of MYC (data not shown). Immunoprecipitation of A2780 extracts with MAX antibody coprecipitates MSH2 (Figure 3b ). MYC antibody also coimmunoprecipitates MSH2, which suggests that these proteins may be present in multiprotein complexes in the cell. Together with the yeast two-hybrid and GST-pull-down experiments, these data indicate that hMLH1 is capable of interacting with c-MYC and hMSH2 with MAX, and that such complexes can be detected to occur in vivo in cells.
Effect of deregulated c-MYC expression on HGPRT mutation rate
Rat fibroblast cells have been previously shown to undergo cell cycle deregulation when c-MYC activity is induced using chimeras of c-MYC and steroid receptors (Eilers et al., 1989) . C-MYC fused to a tamoxifeninducible mutant oestrogen receptor (MYC-ERt) has been particularly exploited as a means of switching on (Littlewood et al., 1995) . We have used this 4OHT-inducible model to examine the potential effects of MYC-ERt expression on the mutator phenotype in rat fibroblasts. The HGPRT mutation rate of MYC-ERt rat fibroblast cells with MYC induced by 4OHT was compared to uninduced cells. Independent clones of the MYC-ERt rat fibroblasts were picked and either grown in the presence of 4OHT to induce MYC-ERt activity, or grown in normal medium. 6-Thioguanine (5 mg/ml) was used to select for HGPRT mutants and the mutation rate calculated using fluctuation analysis allowing for plating efficiency of the cells (Luria and Delbruck, 1943) . In order to control for any potential direct mutagenic effects of the tamoxifen treatment, Rat1 cells, which have not been transfected with MYC-ERt, were treated in an identical manner with 4OHT and HGPRT mutation rate measured. This 4OHT treatment did not significantly (P ¼ 0.34) alter the HGPRT mutation rate (1.8 Â 10 À6 per viable cell, n ¼ 440, after 4OHT treatment and 2.1 Â 10 À6 per viable cell, n ¼ 510, without 4OHT treatment), suggesting that 4OHT had no direct mutagenic effect at HGPRT in these Rat1 cells. Induction of MYC-ERt by 4OHT induced a slight, although statistically significant increase (Po0.0001) in the mutation rate at HGPRT compared to untreated cells. The mutation rate after 4OHT induction of c-MYC was 3.5 Â 10 À6 per viable cell (n ¼ 310) compared to 1.1 Â 10 À6 per viable cell (n ¼ 482) in untreated cultures. A specific frameshift hotspot at a run of six guanine residues at position 206 bp in exon 3 of the HGPRT gene has been previously shown to account for a high proportion of HGPRT mutations in an MMRdeficient background (Bhattacharyya et al., 1994) . None of the 21 resistant clones from MYC-ER cells grown in the absence of 4OHT had mutations in exon 3 of HGPRT; however four out of 25 resistant clones selected from cells grown with MYC induced by 4OHT had a frameshift mutation in exon 3. All the frameshift mutants identified represented a one guanine deletion in the run of six guanines at position 206 of the HGPRT gene.
Discussion
It has been argued that the ability of proteins to interact with one another indicates that they participate in the same or related cellular functions (Oliver, 2000) . We have shown that the proto-oncogene MYC interacts with the MutL homologue MLH1, while MAX, the heterodimeric partner of c-MYC, interacts with the MutS homologue MSH2. Effects of MMR and c-MYC:MAX on cells has many parallels. Thus, loss of MMR, as well as causing increased rates of frameshift mutations, can lead to loss of cell cycle arrest and apoptosis induced by DNA damage, inappropriate progression through the cell cycle and polyploidization (Hawn et al., 1995; Strathdee et al., 2001) . Similarly, deregulated c-MYC expression can also lead to loss of cell cycle checkpoints, DNA damage-induced apoptosis, genetic instability and polyploidization (Prendergast, 1999; Felsher and Bishop, 1999; Adachi et al., 2001) . A broad body of work argues that c-MYC is a transcription factor that activates and represses different target genes (for review, see Cole and McMahon (1999) ). However, there are a large number of studies that suggest that c-MYC has unique roles beyond this involvement with transcription (Cole and McMahon, 1999) .
We have used a number of different in vitro assays to demonstrate these interactions, as well as shown by coimmunoprecipitation that such complexes exist in human tumour cells. Neither the carboxy fragment of c-MYC identified nor MLH1 show any evidence of selfactivation in the yeast two-hybrid assay or nonspecific interactions with irrelevant proteins. Full-length c-MYC was not used in the yeast two-hybrid assay because of self-activation of the construct. However, full-length c-MYC has been shown to interact with MLH1 in the GST-pull-down experiments using IVTT generated c-MYC or cell extracts. In the GST-pull-down and coimmunoprecipitation experiments of cell extracts using conditions that identified interaction between MLH1 and c-MYC or MSH2 and MAX, proteins including PCNA and vinculin (data not shown) showed no evidence of coprecipitation. This argues that under these conditions of stringency MLH1 was not simply sticking to irrelevant proteins. Finally, the presence of these proteins in complexes that can be coimmunoprecipitated from cells argues that these interactions have physiological relevance. Future studies will examine the interaction of these complexes with DNA-containing mismatches or DNA adducts, although the specificity of current antibodies and masking of epitopes in such complexes make such experiments challenging.
Interaction of MLH1 with c-MYC requires an intact c-MYC leucine zipper domain, while the region in MLH1 required for the interactions overlaps with the region required for heterodimerization with other MutL homologues (Kondo et al., 2001) . MAX interaction with MYC also requires the leucine zipper domain of MYC, as do a variety of proteins involved in transcriptional control that interact with MYC (Scully and Livingston, 2000) . The region of MLH1 that interacts with c-MYC overlaps with the region of MLH1 required for heterodimerization with other MutL homologues (amino acids 492-742, Kondo et al., 2001) . Since the interacting domains identified overlap with known interaction sites with other proteins, the interaction of mismatch repair proteins with MYC and MAX may represent only a small fraction of the MMR and c-MYC complexes in the cell. Nevertheless, the coimmunoprecipitation experiments show that such interactions do occur in human tumour cells.
The observation that deregulated c-MYC expression in Rat1 cells induced a significant, albeit minor, increase in the HGPRT mutation rate and in the number of frameshift HGPRT mutants selected does not prove a functional link between c-MYC and/or MAX with MMR proteins. However, subtle variations in MMR mmr interactions with c-MYC and MAX M Mac Partlin et al activity that could lead to such differences in mutation rate will be difficult to detect using in vitro assays of MMR activity in cell extracts (Holmes et al., 1990) . Deregulated c-MYC expression can lead to loss of cell cycle checkpoints and genetic instability (Felsher and Bishop, 1999) . A variety of studies have shown that c-MYC overexpression can lead to genetic instability, although most of these studies have associated c-MYC overexpression with gene amplification or other types of chromosomal instability rather than point mutations such as frameshift mutations (Mai et al., 1996; Rockwood et al., 2002) . The increased HGPRT mutation rate upon induced c-MYC overexpression could be caused by the loss of cell cycle control. However, the altered mutation rates are also consistent with a direct role of c-MYC in modulating MMR activity and giving rise to increased rate of frameshift mutations. The mutations are observed at a specific frameshift hotspot at a run of six guanine residues in exon 3 of the HGPRT gene, which has been previously shown to account for a high proportion of HGPRT mutations in an MMRdeficient background (Bhattacharyya et al., 1994) . Such mutations are only rarely observed in an MMRproficient background. Thus, the increased number of HGPRT frameshift mutants in cells after induction of c-MYC would argue that deregulated c-MYC expression could have an inhibitory effect on MMR activity. It has been argued that in murine models of Burkitt lymphoma that deregulated c-MYC leads to exclusively chromosomal-type aberrations rather than point mutations in a lacZ transgene (Rockwood et al., 2002) . The frameshift point mutations observed in the present study might be because of the different cell types or mutation selection system used. However, a role for MMR in modulating the frequency of illegitimate genetic recombinations giving rise to chromosomal instability is also possible.
Recently, it has been suggested that c-MYC activation can induce DNA damage prior to S phase in normal human fibroblasts (Vafa et al., 2002) . It is feasible that DNA damage induced by deregulated c-MYC may be repaired by MMR or loss of MMR could lead to DNA-damage tolerance. C-MYC induction has been associated with induction of reactive oxygen species (Vafa et al., 2002) . MMR has been implicated in removal of 8-oxoguanine from DNA (Colussi et al., 2002) , while loss of MMR has been implicated in tolerance to oxidative damage (Hardman et al., 2001) . So far, there is no evidence for a direct functional link between c-MYC deregulation, damage induction and mismatch repair. If the c-MYC-induced differences in mutation rate observed in the present study are because of the interactions between c-MYC and MLH1, then the effects on MMR are small. However, while complete depletion of MMR is necessary to reveal genomic instability as detected by microsatellite instability, phenotypic effects on alkylating agent tolerance can be detected in cells with reduced, but not completely lost, MMR activity (Claij and Te Reile, 2002) . Therefore, it is possible that even relatively small effects on MMR activity could have important biological implications in tumour development or the acquisition of resistance to DNA-damaging agents.
Materials and methods
Yeast two-hybrid screen
The carboxy terminus of human c-MYC (amino acids 245-439) was isolated from yeast two-hybrid screens (Clontech Laboratories, Palo Alto, CA, USA) of a Clontech MATCH-MAKER human Normal Mammary Gland cDNA library and a normal Human Ovary cDNA library pooled from five Caucasians, cloned into yeast GAL4 activation domain pACT2, and screened with hMLH1 cloned into the GAL4 DNA-binding domain vector pGBT9. Interacting clones were identified by cotransformation into Saccharomyces cerevisiae host strain Y190, selection on Leu
/His
À drop-out medium in the presence of 25 mm 3-amino-1,2,4-triazole and colonies assayed for b-galactosidase activity. The c-MYC sequences isolated, along with avian c-MYC (amino acids 222-417), were tested individually by cotransformation with either full-length hMLH1 or a carboxy terminus fragment of hMLH1 (amino acids 515-756). The MYC constructs showed no self-activation as assayed by cotransformation with pGBT9 or pGBT9 containing the gene encoding lamin. Mutant forms of avian c-MYC (Crouch et al., 1993) were cloned into the vector pACT2 and tested for interaction with MLH1. The avian c-MYC mutants tested are c-mycD10 (A to T substitution at 1219 bp, AAA to TAA deleting the last 10 amino acids by generating a STOP codon), c-mycD28 and v-mycD28 (A to T substitution at 1165 bp, AGA to TAA deleting the last 28 amino acids by generating a STOP codon), c-mycP-H1 (G to C at 1017 bp, substituting phenylalinine to proline at 353), c-mycP-H2 (A to C at 1129 bp, substituting lysine to proline at 377).
In vitro transcription/translation and GST-pull-down assays PHLmyc0/1 DNA (Hann et al., 1988) was transcribed and translated using the Promega TNT T3 coupledt transcription/ translation system. hMLH1 full length and fragments were obtained by PCR from human cDNA and cloned into the pGEX4T-2 vector (Pharmacia Biotech): MLH1-F1, 42-725 bp; MLH1-F2, 582-1067 bp; MLH1-F3, 966-1778 bp; MLH1-F4, 1584-2312 bp. MAX-GST fusion constructs were as previously described (Crouch et al., 1993) . Proteins interacting with the GST fusion proteins were identified using Western blots with antibodies to c-MYC (rabbit polyclonal C19, Santa Cruz, CA, USA), PMS2 (mouse monoclonal Ab1, Calbiochem) and MSH2 (mouse monoclonal Ab2, Calbiochem) or radiolabelled proteins visualized after electrophoresis and autoradiography.
Immunoprecipitation of cell extracts
Cell extracts were incubated with MLH1, MYC, MAX or control preimmune serum and precipitates analysed by Western blotting. Antibodies used for immunoprecipitation were anti-MYC (rabbit polyclonal C19, Santa Cruz, CA, USA), anti-MAX (rabbit polyclonal, La Rocca et al., 1994) , anti-MSH2 (rabbit polyclonal Ab3 Calbiochem), anti-MLH1 (rabbit polyclonal Ab2, Calbiochem) or preimmune serum (Pre-IS, taken from the rabbit used to raise the anti-MYC serum). Antibodies used for Western analysis were MSH2 (mouse monoclonal Ab2, Calbiochem) and MLH1 (mouse monoclonal G168-15, Pharminogen). In the case of cisplatin treatment (+CP), cells were treated with 20 mm cisplatin for 1 h, 24 h before preparing cell extracts. 
